Mass Spec Alternative Detects Biomarker Signatures in Tissues, Blood, and Cell Culture The current generation of antibody microarray technologies is providing highly sensitive new tools for screening ...
The DNA microarray market is witnessing steady growth due to the rising demand for advanced genomic research, personalized medicine, and early disease diagnosis. The increasing prevalence of cancer, ...
The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...
A prospective pharmacogenetic study of thymidylate synthase (TS) polymorphisms in high risk stage II or stage III colon cancer patients treated with 5-fluorouracil (5-FU) and leucovorin (LV) ...
In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhibitors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results